Myths vs facts: CYP2C19 and Wechseljahre

The claim that CYP2C19 gene variants directly affect menopause (Wechseljahre) is a myth. CYP2C19 is a drug-metabolizing enzyme primarily involved in the breakdown of medications such as clopidogrel, proton pump inhibitors, and certain antidepressants. No robust studies show a causal link between CYP2C19 polymorphisms and the timing or severity of menopausal symptoms. Menopause is driven by hormonal decline (estrogen) and genetic factors like age at menarche or BRCA variants. Some companies market DNA tests including CYP2C19 as a 'hormone test' – this lacks scientific support. The only plausible connection is pharmacogenetic: CYP2C19 may influence the metabolism of hormone replacement therapy (e.g., estrogen) or antidepressants commonly used during menopause. That is a drug-response issue, not a direct menopause effect. Evidence grade: unclear/mechanistic. No human studies directly linking CYP2C19 to menopause outcomes were found in the provided context. Consumers should be skeptical of such claims and consult a healthcare provider for menopause management.